Understanding earwig phenology in top fruit orchards

Earwigs, Forficula auricularia, are key generalist predators to a variety of orchard pests. However, numbers of earwigs have declined in both organic and IPM orchards in recent years. Both Integrated and Organic fruit growers have tried to re-establish earwig populations, thus far with little success. To understand earwig population dynamics and to find measures to increase natural orchard populations, we conducted a detailed phenological survey of earwigs in orchards. Earwigs were sampled while sheltering during daytime in artificial refuges. They move into the trees from the third nymph stage onwards. In most orchards, a small second brood is produced in summer, and this has a positive impact on population size in fall. We see only minor differences in phenology between apple and pear orchards, mainly caused by differences in alternative hiding places. Earwigs show an inexplicable reduction in numbers at the timing of moulting into adults. When earwig phenology is correlated with pest phenology in apple and pear, its use for pest control of major pests is clear

Protection and maintenance of permanent pastures

peer reviewedAll farmers receiving direct payments are subject to compulsory cross-compliance which includes standards related to the maintenance and protection of permanent pastures. Questionnaire techniques and spatio-temporal analyses demonstrated that the ratio of permanent pasture area to agricultural land provides a simple tool for monitoring and controlling the protection of permanent pastures at the regional to Member State level. Huge variations in the ratio across Europe were related to the importance of permanent pastures, the interpretation of definitions, sources of information used, differences in calculation, and the presence of protective and/or sensitive zones. Precautionary or complementary measures are in place in most Member States in order to prevent decreases in the ratio. The implementation of GAEC standards related to permanent pastures overlaps with the standard management requirements, national legislation and current agri-environmental programmes. The study advocates the establishment of a comprehensive geo-information platform consisting of a topologically correct inventory of all permanent pasture parcels in a 1:1 geo-referenced relation between IACS and LPIS; ancillary spatially explicit data such as orthophotos, remote sensing images and other thematic geo-databases; and, geodatabases with parcel information compiled for other monitoring purposes such as those within the framework of the Nitrates Directive or 2nd pillar support

Enhancing LULC scenarios impact assessment in hydrological dynamics using participatory mapping protocols in semiarid regions

Land use and land cover (LULC) scenarios in rural catchment hydrology are crucial to describe the effects of future water dynamics. However, there is a lack of understanding of the effectiveness of including static land covers at the subbasin level to provide inter-annual stability in changing the different water balance components. We developed a step-by-step mapping protocol to extend and enrich the hydrological assessment of future LULC scenarios defined through participatory stakeholder involvement. This novelty included specific allocation of static and dynamic LULC change among the scenarios and then compared the change of water dynamics to the current situation. For this, we quantified the LULC impact on the components of the water balance from three contrasting participatory scenarios implemented with the SWAT model in a rural basin in central Spain. The Land-sharing scenario (LSH) had the highest percentage of permanent grassland and shrubs and no increase of irrigated land compared to baseline. The land-sparing scenario (LSP) intensified agricultural land use close to urban areas, and the land balance scenario (LBA) was intermediate. The LSH increased the aquifer recharge by +1.7% and streamflow by +1.5%, while evapotranspiration and soil water storage decreased by -0.2%. In contrast, the LBA decreased in the riverine flux of -0.5%, an aquifer recharge of -0.6%, a soil water storage of -3.5%, and an evapotranspiration rate of +0.3%. Thus, LSH revealed that the allocation of permanent land cover such as grassland could buffer water dynamics, suggesting that dedicated planning and allocation of permanently vegetated LULC will favour land and water conservation

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine kinase inhibitor, was originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that imatinib mesylate inhibits osteoclast differentiation through the M-CSFR pathway and activates osteoblast differentiation through PDGFR pathway, two key cells involved in the vicious cycle controlling the tumour development. The present study investigated the in vitro effects of imatinib mesylate on the proliferation, apoptosis, cell cycle, and migration ability of five osteosarcoma cell lines (human: MG-63, HOS; rat: OSRGA; mice: MOS-J, POS-1). Imatinib mesylate was also assessed as a curative and preventive treatment in two syngenic osteosarcoma models: MOS-J (mixed osteoblastic/osteolytic osteosarcoma) and POS-1 (undifferentiated osteosarcoma). Imatinib mesylate exhibited a dose-dependent anti-proliferative effect in all cell lines studied. The drug induced a G0/G1 cell cycle arrest in most cell lines, except for POS-1 and HOS cells that were blocked in the S phase. In addition, imatinib mesylate induced cell death and strongly inhibited osteosarcoma cell migration. In the MOS-J osteosarcoma model, oral administration of imatinib mesylate significantly inhibited the tumour development in both preventive and curative approaches. A phospho-receptor tyrosine kinase array kit revealed that PDGFRα, among 7 other receptors (PDFGFRβ, Axl, RYK, EGFR, EphA2 and 10, IGF1R), appears as one of the main molecular targets for imatinib mesylate. In the light of the present study and the literature, it would be particularly interesting to revisit therapeutic evaluation of imatinib mesylate in osteosarcoma according to the tyrosine-kinase receptor status of patients

Repair and Reconstruction of a Resected Tumor Defect Using a Composite of Tissue Flap–Nanotherapeutic–Silk Fibroin and Chitosan Scaffold

A multifaceted strategy using a composite of anti-cancer nanotherapeutic and natural biomaterials silk fibroin (SF) and chitosan (CS) blend scaffolds was investigated for the treatment of a tissue defect post-tumor resection by providing local release of the therapeutic and filling of the defect site with the regenerative bioscaffolds. The scaffold-emodin nanoparticle composites were fabricated and characterized for drug entrapment and release, mechanical strength, and efficacy against GILM2 breast cancer cells in vitro and in vivo in a rat tumor model. Emodin nanoparticles were embedded in SF and SFCS scaffolds and the amount of emodin entrapment was a function of the scaffold composition and emodin loading concentration. In vitro, there was a burst release of emodin from all scaffolds during the first 2 days though it was detected even after 24 days. Increase in emodin concentration in the scaffolds decreased the overall elastic modulus and ultimate tensile strength of the scaffolds. After 6 weeks of in vivo implantation, the cell density (p < 0.05) and percent degradation (p < 0.01) within the remodeled no emodin SFCS scaffold was significantly higher than the emodin loaded SFCS scaffolds, although there was no significant difference in the amount of collagen deposition in the regenerated SFCS scaffold. The presence and release of emodin from the SFCS scaffolds inhibited the integration of SFCS into the adjacent tumor due to the formation of an interfacial barrier of connective tissue that was lacking in emodin-free SFCS scaffolds. While no significant difference in tumor size was observed between the in vivo tested groups, tumors treated with emodin loaded SFCS scaffolds had decreased presence and size and similar regeneration of new tissue as compared to no emodin SFCS scaffolds

Drugs in early clinical development for the treatment of osteosarcoma

Introduction: Osteosarcomas are the main malignant primary bone tumours found in children and young adults. Conventional treatment is based on diagnosis and resection surgery, combined with polychemotherapy. This is a protocol that was established in the 1970s. Unfortunately, this therapeutic approach has reached a plateau of efficacy and the patient survival rate has not improved in the last four decades. New therapeutic approaches are thus required to improve the prognosis for osteosarcoma patients. Areas covered: From the databases available and published scientific literature, the present review gives an overview of the drugs currently in early clinical development for the treatment of osteosarcoma. For each drug, a short description is given of the relevant scientific data supporting its development. Expert opinion: Multidrug targeted approaches are set to emerge, given the heterogeneity of osteosarcoma subtypes and the multitude of therapeutic responses. The key role played by the microenvironment in the disease increases the number of therapeutic targets (such as macrophages or osteoclasts), as well as the master proteins that control cell proliferation or cell death. Ongoing phase I/II trials are important steps, not only for identifying new therapies with greater safety and efficacy, but also for better defining the role played by the microenvironment in the pathogenesis of osteosarcoma